Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation

This article reviews data on the assessment of the incidence of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA, arthropathic psoriasis), as well as related disability and the economic burden of these nosological entities, including their therapy with biological agents. It considers the issues of organization and quality of medical care, drug supply, normative and legal regulation. The paper also shows the important epidemiological and socioeconomic importance of RA, AS, and PsA in Russia, points out the regional peculiarities of medical care and drug provision, and proposes solutions for their optimization at the federal and local levels. In preparing this investigation, the authors have taken into account the opinions of many specialists and experts in this field from different subjects of the Russian Federation.

1. Folomeeva OM, Nasonov EL, Andrianova IA. Rheumatoid arthritis in rheumatological care of Russia: the severity of the disease in a russian patient population: a cross-sectional epidemiological study (RAISER). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2010;48(1):50-60. (In Russ.). doi: 10.14412/1995-4484-2010-1406

2. https://www.lvrach.ru/news/4952193/,http://r-factor.ru/ra.htm

3. The Ministry of health of the Russian Federation, Department of monitoring, analysis, and strategic development of health care, «Central scientific-research Institute of organization and Informatization of health» of Ministry of health of Russia. Zabolevaemost' vsego naseleniya Rossii v 2016 godu. Statisticheskie materialy [Morbidity of the whole population of Russia in 2016. Statistical data]. Moscow; 2017.

4. The Ministry of health of the Russian Federation. Clinical guidelines. Ankylosing spondylitis (КР 252). http://cr.rosminzdrav.ru/#!/schema/175

5. Federal'nye klinicheskie rekomendatsii. Dermatovenerologiya-2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem [Federal clinical guidelines. Dermatology 2015: diseases of the skin. Sexually transmitted infections]. 5th edition. Moscow: Delovoi ekspress; 2016. 768 p.

6. Olivieri I, Padula A, D’Angelo S, Cutro MS. Psoriatic arthritis sine psoriasis. J Rheumatol Suppl. 2009 Aug;83:28-9. doi: 10.3899/jrheum.090218.

7. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005 Oct;53(4):573.

8. Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an over-view. Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii8-18.

9. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol Suppl. 1989;79:67-96.

10. Fex E, Larsen BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and leisure time activities in patients followed 8 years from onset. J Rheumatol. 1998 Jan;25(1):44-50.

11. Folomeeva OM, Lobareva LS, Ushakova MA. Disability due to rheumatic diseases among residents of the Russian Federation. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2001;39(1):15-21. (In Russ.).

12. Adzhigaitkanova SK. Diagnostika i lechenie otdel'nykh form revmaticheskikh zabolevanii s pozitsii dokazatel'noi meditsiny [Diagnosis and treatment of certain forms of rheumatic diseases from the standpoint of evidence-based medicine]. Moscow: GBOU VPO RNIMU im. N.I.Pirogova; 2013.

13. Haugeberg G, Hansen IJ, Soldal DM, Sokka T. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther. 2015 Aug 20;17:219. doi: 10.1186/s13075015-0716-0.

14. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian arthritis registry data (communication 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84. (In Russ.). doi: 10.14412/1995-4484-2015472-484

15. Erdes ShF, Folomeeva OM, Tel'nykh MYu, et al. Results of a cross-sectional epidemiological study determining the needs for genetic engineering biologicals for therapy in patients with rheumatoid arthritis in real clinical practice in Russia (IRACL). Communication 2. Determination of needs for genetic engineering biologicals. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2010;48(4):40-8. (In Russ.). doi: 10.14412/1995-4484-2010-1164

16. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015 Feb;74(2):415-21. doi: 10.1136/annrheumdis-2013-204021. Epub 2013 Nov 29